Body Weight Gain, Parkinson, Subthalamic Stimulation

Mechanisms of Body Weight Gain in Patients With Parkinson's Disease After Subthalamic Stimulation

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00529724

Enrollment

Registered

2007-09-14

Start date

2007-09-03

Completion date

2018-06-01

Last updated

2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

Energy metabolism, metabolic syndrome, by chronic bilateral subthalamic stimulation, Parkinson's disease, Patients with Parkinson's disease and will be treated by chronic bilateral subthalamic stimulation.

Brief summary

Chronic bilateral subthalamic stimulation leads a spectacular clinical improvement in patients with motor complications. However, the post-operative body weight gain involved may limit the benefits of surgery and induce critical metabolic disorder. The aim of this study to determine the energy expenditure in usual conditions of life.

Detailed description

Patients will be studied before (between 3 and 1 months) and after (1 month) STN-DBS surgery. Each time the same measurements will be taken. The principal ones will be : * Clinical examination * Autoevaluation dietary questionnaire * Biological tests * Study in calorimetry chamber (only in Clermont-Ferrand centre) * Heart rate recorded during 7 days in usual conditions of life * Energy expenditure recorded during 14 days in usual conditions of life with normalized water (18O 10 %) and Deuterium oxide (99.94 %D) * Acute Ldopa challenge (in both conditions of dopa and stim) * Apathy evaluation * Body weight, and body compositions measurements

Interventions

BEHAVIORALEnergy metabolism by chronic bilateral subthalamic stimulation

Patients will be studied before and after STN-DBS surgery

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Aged between 18 and 70 years old * Diagnosis of Parkinson' disease established for 5 years at least * Ldopa effect \> 50 % * Hoehn and Yarh score \> 2.5 in On phase

Exclusion criteria

* Metabolism disorder * Biological analysis abnormal

Design outcomes

Primary

Measure	Time frame
heart rate recorded during 7 days in usual conditions of life	7 days in usual conditions of life
energy expenditure recorded during 14 days in usual conditions of life with normalized water (18O 10 %) and Deuterium oxide (99.94 %D)	14 days in usual conditions of life

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026